Stocktoria
IRADIMED CORP IRMD
IRADIMED CORP financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.8M | $73.2M | $65.6M | $53.3M | $41.8M | $31.7M | $38.5M | $30.4M | $23.1M | $32.5M |
| Gross profit | $64.3M | $56.4M | $50.2M | $41.3M | $32.0M | $23.6M | $29.7M | $23.2M | $17.5M | $26.3M |
| R&D expense | $3.0M | $2.8M | $2.9M | $2.3M | $1.9M | $1.9M | $1.4M | $1.5M | $1.7M | $1.3M |
| Operating income | $26.1M | $22.0M | $20.0M | $15.6M | $9.8M | -$756,091 | $8.6M | $6.0M | $1.3M | $10.9M |
| Income tax | $5.9M | $5.0M | $4.5M | $3.4M | $510,816 | -$2.0M | -$587,642 | -$106,143 | $896,622 | $3.7M |
| Net income | $22.5M | $19.2M | $17.2M | $12.8M | $9.3M | $1.4M | $9.6M | $6.3M | $499,764 | $7.2M |
| EPS (diluted) | $1.75 | $1.50 | $1.35 | $1.02 | $0.74 | $0.11 | $0.78 | $0.52 | $0.04 | $0.60 |
| Operating cash flow | $24.9M | $25.6M | $13.5M | $10.0M | $11.3M | $5.8M | $10.2M | $7.4M | $3.4M | $9.4M |
| Free cash flow | $17.2M | $17.6M | $6.0M | $9.2M | $10.8M | $5.4M | $9.9M | $7.1M | $2.6M | $8.6M |
| Cash & equivalents | $51.2M | $52.2M | $49.8M | $58.0M | $62.0M | $50.1M | $43.5M | $28.0M | $18.2M | $17.7M |
| Inventory | $11.6M | $10.4M | $12.8M | $5.4M | $4.3M | $3.9M | $3.6M | $4.1M | $4.2M | $3.9M |
| Total assets | $108.8M | $98.3M | $92.2M | $85.5M | $82.9M | $71.1M | $66.7M | $48.4M | $39.0M | $37.2M |
| Total liabilities | $14.2M | $11.5M | $20.7M | $11.8M | $10.7M | $9.7M | $11.2M | $6.5M | $6.1M | $5.3M |
| Shareholders' equity | $94.6M | $86.8M | $71.4M | $73.7M | $72.2M | $61.4M | $55.5M | $41.9M | $32.9M | $31.9M |
Growth · year-over-year · Revenue CAGR 11.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +14.4% | +11.7% | +23.0% | +27.5% | +31.8% | -17.7% | +26.5% | +31.9% | -29.0% | +2.9% |
| Net income growth | +16.9% | +11.9% | +34.0% | +37.6% | +581.2% | -85.8% | +52.8% | +1161.3% | -93.1% | -4.2% |
| EPS growth | +16.7% | +11.1% | +32.4% | +37.8% | +572.7% | -85.9% | +50.0% | +1200.0% | -93.3% | +0.0% |
| Free cash flow growth | -2.5% | +192.5% | -34.7% | -14.4% | +100.5% | -45.5% | +38.0% | +170.7% | -69.4% | +17.3% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.